Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?
By E. Creemers, A. Tijsen, Y. Pinto. Circulation Research, 2012
1,033 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/74cb04525fbc044d7a70a00db39784cf4262f9c5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- M. Krenz
- Yuan Zhou
- Juan Wang
- Qinghua Cui
- Ronald J. Korthuis
- Christopher P. Baines
- Jichun Yang
- Theodore J Kalogeris
In Molecular Biology
- M. Krenz
- Yuan Zhou
- Juan Wang
- Qinghua Cui
- T. Jiang
- Ronald J. Korthuis
- Christopher P. Baines
- Jichun Yang
Citations in the corpus
- Ischemia/Reperfusion (2016, neutral): “miRNAs have the potential to participate in the pathogenesis of I/R injury (86, 162, 277, 281, 297, 492, 517, 688, 691, 866, 887, 894).”
- TransmiR v2.0: an updated transcription factor-microRNA regulation database (2018, background): “In recent years, abundant evidence has shown that the deregulation of specific miRNA is associated with various diseases like cancers (2,4), cardiovascular diseases (5,6), and psychiatric disorders (7,8).”
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, background): “well-defined outcome measures and prognostic accura y before they can reach the clinical arena (77-84) .”
- The Host Shapes the Gut Microbiota via Fecal microRNA (2016, neutral): “, 2010), whether fecal miRNAs could exist in EV-free forms, such as associating with high-density lipoproteins or argonaute protein (Creemers et al., 2012), or in a completely free form, needs further investigation.”
- Cell Biology of Ischemia/Reperfusion Injury (2012, background): “Circulating miRNAs can be detected in serum or plasma in a remarkably stable form, which support their potential use as biomarkers for cardiovascular disease (Abdellatif, 2012; Creemers et al., 2011; Kukreja et al., 2011).”
- Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets (2015, background): “The role of circulating miRNAs has also received considerable attention because they have been detected in serum and plasma of animals and patients with failing hearts, opening the possibility of using miRNAs as biomarkers of disease states (Creemers et al. 2012).”
- HMDD v2.0: a database for experimentally supported human microRNA and disease associations (2013, background): “More recently, increasing studies have revealed that a number of miRNAs stably exist in circulation systems and could be biomarkers for disease diagnosis and treatment (22).”